The efficacy of the cognitive behavioral therapy for overactive bladder in women: a randomized controlled trial

The efficacy of the cognitive behavioral therapy for overactive bladder in women: a randomized controlled trial - The efficacy of the cognitive behavioral therapy for overactive bladder in women: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038513

Enrollment

150

Registered

2019-12-01

Start date

2020-01-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

Interventions

Cognitive behavioral therapy for overactive bladder in women (30 minutes/ session, once a week, total 4 sessions) Waiting list

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Patients with no treatment or more than 6 weeks pharmacotherapy for OAB. 2. Participants diagnosed as OAB by OAB symptom score (OABSS) and total score is more than 6 points (moderate or more). 3. Fully active, able to carry on all pre-disease performance without restriction (ECOG Performance Status: Grade 0). 4. Participants who understand explanation and obtain written informed consent.

Exclusion criteria

Exclusion criteria: 1. Participants has abnormality around the bladder (e.g., bladder stone, urethral stone, interstitial cystitis, endometriosis, pelvic organ prolapse). 2. Participant is diagnosed as Urinary Tract Infection (UTI). 3. Participants who have had surgery for urinary incontinence. 4. Pregnant or possibly pregnant participants. 5. Participants who can not understand the notation of Japanese. 6. Participants with depressed tendency. 7. Participants who are diagnosed as dementia. 8. Participants who are considered as inappropriate for this study by the responsible doctor

Design outcomes

Primary

Measure	Time frame
HRQoL total score of Overactive bladder questionnaire (OAB-q)	—

Secondary

Measure	Time frame
1. The other score of Overactive bladder questionnaire (OAB-q) 2. Overactive bladder symptom score (OABSS) 3. King's health questionnaire (KHQ) 4. Patient Global Impression-Improvement (PGI-I) 5. Patient Global Impression-Severity (PGI-S) 4. Euroqol-5D-5L (EQ-5D-5L) 5. Hospital Anxiety and Depression Scale (HADS) 6. Frequency volume chart 7. Participant satisfaction 8. Change of drug therapy 9. Adherence of treatment 10. Drop-out rate 11. Adverse events 12. Participant feedback	—

Measure

Time frame

1. The other score of Overactive bladder questionnaire (OAB-q) 2. Overactive bladder symptom score (OABSS) 3. King's health questionnaire (KHQ) 4. Patient Global Impression-Improvement (PGI-I) 5. Patient Global Impression-Severity (PGI-S) 4. Euroqol-5D-5L (EQ-5D-5L) 5. Hospital Anxiety and Depression Scale (HADS) 6. Frequency volume chart 7. Participant satisfaction 8. Change of drug therapy 9. Adherence of treatment 10. Drop-out rate 11. Adverse events 12. Participant feedback

—

Countries

Japan

Contacts

Public ContactSatoshi Funada

Kyoto University, Graduate School of Medicine Urology

OAB.CBT@gmail.com050-5374-4457

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026